Vaccine plus immune treatment for newly diagnosed brain stem tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a newly diagnosed DIPG or DMG tumor in the brain stem (not a previous cancer treatment).
- Your diagnosis must be confirmed (with biopsy for some cases) and the tumor’s histone change must be confirmed on pathology.
- You’re between 12 months and 18 years old, and the study may focus first on patients age 12+.
- You can start radiation within 42 days of the diagnostic imaging, and the first study dose must be 6–10 weeks after starting radiation.
- You must be able to measure the tumor on scans and have adequate overall functioning (Lansky/Karnofsky score above the trial’s threshold).
- You should not take temozolomide during radiation, and you should not have certain immune problems or active infections.
- You must not have cancer spread to other areas (disseminated disease) or receive any cancer treatment other than radiation before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This trial tests a vaccine that may help the immune system fight brain tumors (medulloblastoma, high-grade glioma, and DIPG). It is for patients who have already had standard treatment and whose tumors are still present or have returned.
This Phase 1 trial tests a type of cancer-fighting virus given directly into the tumor for children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The goal is to see if it can be delivered safely and to learn how the body responds to it.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This trial tests whether a new drug called VRT106, given alongside radiation therapy, can help treat a serious type of brain tumor called diffuse midline glioma or DIPG. The drug is designed to work with radiation to fight the cancer.
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.